Toll-interacting protein may affect doxorubicin resistance in hepatocellular carcinoma cell lines.

Ayse Banu Demir Elif BarisUmay Bengi KanerHani Alotaibi Neşe Atabey Ahmet Koc

Published in: Molecular biology reports (2023)

Our results showed for the first time that silencing TOLLIP in hepatocellular carcinoma cells may help sensitize these cells to doxorubicin and increase the efficacy of chemotherapeutic regimens where doxorubicin is used.

Keyphrases

drug delivery
cancer therapy
induced apoptosis
cell cycle arrest
signaling pathway